The nausea started gradually, but within months of taking Ozempic, you couldn’t keep food down. Your stomach felt paralyzed, and emergency room visits became routine—a reality thousands now face after trusting these diabetes and weight-loss medications. Medical bills pile up while you miss work for constant doctor appointments, and insurance companies question whether the drug really caused your suffering.
Tell us about your situation to see if you have a case.
You deserve answers, compensation for your injuries, and an experienced legal team who understands both the medicine and the law. Call us at (314) 408-6136 for a free consultation with no upfront costs to discuss your potential claim. At OnderLaw, we’ve recovered over $5 billion in negotiated settlements for clients harmed by dangerous drugs, and we’re prepared to fight for the justice you deserve against pharmaceutical giants who put profits before patient safety.
Unlike many firms that treat clients like case numbers, we provide direct attorney access throughout your case, ensuring you work with experienced lawyers who understand both the legal complexities and personal challenges you’re facing after a serious collision.
“Every case is an opportunity to protect someone else’s family from tragedy”
GLP-1 receptor agonists like Ozempic were marketed as breakthrough treatments, but manufacturers minimized serious risks that have caused devastating digestive complications for thousands of patients. Understanding how these drugs affect your body and the warning signs of gastroparesis is critical for protecting your health and legal rights.
Semaglutide, the active ingredient in Ozempic and Wegovy, belongs to a class called GLP-1 receptor agonists that fundamentally alter how your digestive system processes food by slowing gastric emptying to create feelings of fullness. The FDA first approved Ozempic for Type 2 diabetes treatment in 2017, followed by Wegovy for weight management in 2021, though doctors increasingly prescribed these medications off-label for weight loss even before formal approval. While slowing digestion might sound benign, this mechanism can spiral into dangerous territory when the stomach’s normal motility becomes severely impaired or stops altogether, trapping food for days or weeks. According to the CDC (2024), over 12 million Americans now take GLP-1 receptor agonists, many unaware that the drug’s core mechanism—delaying stomach emptying—can become permanent rather than temporary. Missouri pharmacies dispensed these medications at unprecedented rates, with prescriptions increasing 300% between 2021 and 2024, often without adequate counseling about gastroparesis risks that manufacturers knew or should have known about based on clinical trial data and post-market surveillance reports.
Gastroparesis, literally meaning “stomach paralysis,” occurs when your stomach muscles lose their ability to contract normally, leaving food trapped and fermenting in your digestive system for dangerously long periods. Initial symptoms might seem manageable—bloating, early fullness, mild nausea—but gastroparesis progressively worsens to severe vomiting, malnutrition, bezoar formation (solid masses of undigested food), and life-threatening dehydration requiring hospitalization. The condition creates a cascade of complications: bacterial overgrowth from stagnant food, unpredictable blood sugar spikes despite medication, severe weight loss from inability to eat, and psychological trauma from constant nausea and social isolation. According to FDA adverse event data (2023), approximately 1% of Ozempic users develop gastroparesis, though experts suspect underreporting since many patients don’t immediately connect their symptoms to the medication.
Unlike temporary side effects that resolve after stopping the drug, gastroparesis can persist indefinitely because the nerve damage and muscle dysfunction may become permanent, leaving patients with a lifelong disability. The delayed gastric emptying that semaglutide intentionally causes can cross a critical threshold where the stomach essentially forgets how to function, and no current treatment can reliably restore normal motility once this damage occurs. For many patients, the realization that their weight-loss medication has caused irreversible harm comes too late, after months of suffering and mounting medical expenses that insurance companies may refuse to cover.
Our greatest results have been the relationships we’ve forged with clients we’ve helped and the lives they’ve achieved after horrific accidents with the settlements our work brought about.
Every case is different and handled differently, but we are proud of what we have accomplished on behalf of previous clients. From multi billion dollar mass tort settlements to individual personal injury verdicts, we fight for every penny of compensation our clients deserve.
Past results do not guarantee future outcomes, every case is different*
Determining eligibility for semaglutide litigation requires meeting specific medical and legal criteria that establish both injury severity and causal connection to the medication. Understanding these qualification standards helps you assess whether your experience with Ozempic warrants legal action and what evidence you’ll need to support your claim.
Qualifying diagnoses for Ozempic lawsuits typically include gastroparesis confirmed by gastric emptying study, intestinal obstruction requiring surgical intervention, chronic vomiting syndrome lasting more than three months, or severe malnutrition requiring feeding tube placement. Duration of use matters significantly—most successful claims involve patients who took semaglutide for at least three months before developing symptoms, as this timeframe strengthens the causal relationship between medication and injury. The severity threshold generally requires symptoms that substantially interfere with daily activities, necessitate ongoing medical treatment, or cause permanent digestive dysfunction that persists despite discontinuing the medication.
Many people ask whether mild nausea supports litigation—while mild side effects don’t typically qualify, they should be documented as they may worsen over time or indicate developing gastroparesis. Off-label use for weight loss rather than diabetes doesn’t disqualify your claim; in fact, it may strengthen failure-to-warn arguments since manufacturers knew doctors prescribed semaglutide beyond approved indications without providing adequate risk information for this expanded use. Cases also consider pre-existing conditions, though having prior digestive issues doesn’t automatically bar recovery if Ozempic substantially worsened your condition beyond its baseline state, creating new complications that wouldn’t have occurred without the medication.
Building a strong case requires assembling comprehensive medical records that tell the complete story of your injury, from the first prescription through ongoing treatment for gastroparesis complications. Prescription records must show exact dates, dosages, and duration of semaglutide use, including any dose escalations that may have increased your risk of developing severe gastrointestinal problems. Diagnostic imaging becomes crucial evidence: gastric emptying studies provide objective proof of delayed motility, upper endoscopies document stomach damage or food retention, and CT scans may reveal intestinal obstructions or other complications requiring emergency intervention. Your treatment history should include all healthcare providers involved in your care—primary physicians who prescribed Ozempic, gastroenterologists who diagnosed gastroparesis, emergency room visits for acute symptoms, and any surgeons who performed procedures to address complications.
Economic documentation extends beyond medical bills to encompass lost wages, reduced earning capacity if you can’t return to previous work, out-of-pocket expenses for medications and travel to appointments, and costs for dietary modifications or feeding supplements necessitated by your condition. Our dangerous drug attorneys also recommend maintaining a symptom diary documenting daily struggles with eating, vomiting episodes, pain levels, and how gastroparesis affects your work, relationships, and quality of life—personal accounts that humanize the statistics and convey your suffering’s true impact to judges and juries.
Missouri product liability law provides multiple pathways for holding drug manufacturers accountable when their medications cause serious harm, particularly when companies fail to adequately warn about known or knowable risks. These legal principles now apply to the growing number of gastroparesis cases linked to semaglutide products, where evidence suggests manufacturers prioritized market expansion over patient safety.
The legal framework recognizes that pharmaceutical companies possess superior knowledge about their products’ dangers and bear responsibility for communicating those risks to doctors and patients through comprehensive labeling. When manufacturers fail in this duty, injured patients may be able to pursue compensation through several legal theories, each addressing different aspects of corporate negligence and misconduct.
The legal proceedings against semaglutide manufacturers have rapidly evolved from scattered individual lawsuits to coordinated federal litigation involving thousands of plaintiffs nationwide. Understanding this litigation structure helps you grasp how your case fits within the broader legal strategy and what to expect as proceedings advance toward resolution.
Federal judges consolidated Ozempic gastroparesis cases into a Multidistrict Litigation (MDL) in June 2024, with Judge Karen Marston overseeing coordinated pretrial proceedings that streamline discovery and avoid duplicative efforts across numerous lawsuits. Unlike class actions where one outcome binds all participants, MDL preserves your individual claim while benefiting from shared resources, coordinated expert development, and consistent legal strategies that strengthen everyone’s cases. According to publicly available court records (2025), approximately 2,676 pending lawsuits now comprise the MDL, with new cases transferring monthly as more patients connect their gastroparesis to semaglutide use and seek legal representation. The MDL process allows plaintiffs’ attorneys to pool resources for expensive litigation against well-funded pharmaceutical companies, sharing costs for expert witnesses, document review, and scientific research that individual cases couldn’t afford. Bellwether trials—representative cases selected for early trial dates—will likely begin in 2026, providing crucial insights into how juries respond to evidence and what settlement values might emerge. Working with attorneys who understand MDL procedures ensures your case receives proper attention despite being part of larger proceedings, as individual factors like injury severity, medical history, and economic losses still determine your specific compensation.
While no Ozempic cases have reached trial verdicts yet, settlement values in pharmaceutical litigation typically reflect injury severity, duration of suffering, economic losses, and the defendant’s culpability in concealing or minimizing known risks. Gastroparesis cases may stratify into tiers based on objective criteria: permanent gastroparesis requiring ongoing treatment may command higher values than temporary symptoms that resolved after discontinuing semaglutide. Economic damages include past and future medical expenses, lost wages during treatment and recovery, diminished earning capacity if gastroparesis prevents returning to previous employment, and costs for dietary modifications, medications, and assistive care necessitated by your condition. Non-economic damages compensate for pain and suffering, loss of life enjoyment when you can’t participate in previous activities, emotional distress from chronic nausea and social isolation, and relationship strain when gastroparesis affects intimacy and family dynamics. Missouri law permits punitive damages when manufacturers’ conduct shows deliberate indifference to consumer safety, with damages capped at the greater of $500,000 or five times compensatory damages (RSMo §510.265, current), though federal court application may differ based on jurisdictional considerations.
The legal proceedings against semaglutide manufacturers have rapidly evolved from scattered individual lawsuits to coordinated federal litigation involving thousands of plaintiffs nationwide. Understanding this litigation structure helps you grasp how your case fits within the broader legal strategy and what to expect as proceedings advance toward resolution.
Recognizing that Ozempic caused your gastroparesis marks just the beginning of a journey toward recovery and justice that requires strategic planning and prompt action. The steps you take immediately after discovering the connection between your suffering and semaglutide can significantly impact both your health outcomes and legal options.
Your first priority remains medical stabilization—work with your healthcare providers to manage gastroparesis symptoms, explore treatment options, and document the condition’s impact on your daily functioning and overall health.
Preserve all evidence related to your Ozempic use: keep medication bottles, pharmacy records, insurance statements, and any patient information materials you received when starting the drug, as these documents prove crucial for establishing timeline and dosage.
Report your adverse event to the FDA’s MedWatch system, which not only contributes to public safety surveillance but also creates an official record of your injury that may support your legal claim.
Avoid discussing your potential lawsuit on social media or with insurance adjusters who may contact you; seemingly innocent statements can be misconstrued to minimize your injuries or suggest alternative causes for your gastroparesis.
Begin documenting your daily struggles through a symptom journal, photographing visible effects like extreme weight loss, and saving receipts for all expenses related to your condition—evidence that helps quantify both economic and non-economic damages.
Contact experienced attorneys who can evaluate your case during a free consultation, explain your legal options without obligation, and begin preserving evidence before it disappears or becomes harder to obtain, as early legal involvement often strengthens cases by ensuring proper documentation from the outset.
Missouri’s five-year statute of limitations for product liability claims (RSMo §516.120) might seem generous, but multiple factors make prompt action crucial for protecting your rights and maximizing potential recovery. Evidence quality deteriorates over time—medical records get archived or destroyed, witnesses’ memories fade, and digital communications disappear—making early case development essential for building strong claims. The MDL’s progression creates strategic timing considerations: cases filed earlier may influence bellwether selection, benefit from initial discovery efforts, and position themselves advantageously for potential settlement negotiations.
Insurance coverage for ongoing gastroparesis treatment may depend on establishing clear causation quickly, and some policies have notice requirements that affect your ability to recover medical expenses through litigation. Your body’s response to gastroparesis also evolves—what seems like temporary discomfort might develop into permanent disability, or initial improvement might give way to chronic symptoms, making ongoing medical documentation crucial for capturing the full scope of your injuries. Our attorneys must also coordinate with treating physicians while relationships remain fresh, as doctors who’ve recently treated you provide more compelling testimony than those recalling patients from years past, and their contemporaneous notes carry greater evidentiary weight than reconstructed memories.
Economic damages include past and future medical expenses, lost wages during treatment and recovery, diminished earning capacity if gastroparesis prevents returning to previous employment, and costs for dietary modifications, medications, and assistive care necessitated by your condition.
Non-economic damages compensate for pain and suffering, loss of life enjoyment when you can’t participate in previous activities, emotional distress from chronic nausea and social isolation, and relationship strain when gastroparesis affects intimacy and family dynamics.
Missouri law permits punitive damages when manufacturers’ conduct shows deliberate indifference to consumer safety, with damages capped at the greater of $500,000 or five times compensatory damages (RSMo §510.265, current), though federal court application may differ based on jurisdictional considerations.
According to FDA adverse event data (2023), approximately 1% of Ozempic users develop gastroparesis, though this figure likely underrepresents true incidence due to underreporting and delayed diagnosis. Many patients don’t immediately connect digestive symptoms to their medication, and mild cases may go undiagnosed until symptoms become severe enough to warrant specialized testing. The risk appears to increase with higher doses and longer duration of use, particularly in patients who rapidly escalate dosage for enhanced weight loss effects, suggesting that the actual incidence may be higher than reported figures indicate.
Yes, you can file a lawsuit while still taking Ozempic, but consult with your doctor about safely discontinuing the medication if possible, as continuing use may complicate causation arguments and suggest that benefits outweigh risks. Some patients cannot stop taking semaglutide due to diabetes management needs, and courts recognize that medical necessity doesn’t bar recovery for injuries caused by inadequate warnings. Document your discussions with healthcare providers about risks versus benefits, as these conversations demonstrate you would have made different choices with complete information about gastroparesis risks.
Ozempic lawsuits focus specifically on gastrointestinal injuries, particularly gastroparesis and intestinal obstruction, rather than the varied injuries seen in other pharmaceutical litigation. The mechanism of injury—intentionally delayed gastric emptying that becomes pathological—creates unique causation arguments about when therapeutic effect becomes harmful side effect. These cases also involve significant off-label prescribing for weight loss, raising additional questions about manufacturers’ duties to warn about risks in expanded patient populations beyond approved uses, and the distinction between cosmetic and medical necessity affects how juries may view risk-benefit calculations.
Off-label use for weight loss may still qualify for compensation, as manufacturers knew doctors widely prescribed semaglutide for this purpose and had duties to provide adequate warnings for foreseeable uses. In fact, off-label weight loss use might strengthen failure-to-warn claims, since you accepted risks for cosmetic rather than medical benefits and might have made different choices with complete gastroparesis information. Courts recognize that FDA approval for one indication doesn’t absolve manufacturers from warning about risks relevant to common off-label uses, particularly when companies actively promoted such uses through marketing strategies that encouraged physicians to prescribe beyond approved indications.
Gastroparesis symptoms can persist indefinitely after discontinuing Ozempic, as the condition involves nerve and muscle damage that may become permanent rather than reversible. Some patients experience gradual improvement over months or years, while others require lifelong management with dietary modifications, medications, and potentially surgical interventions. The unpredictable duration and potential permanence of gastroparesis makes these injuries particularly serious and may support significant damage awards for ongoing suffering and medical needs, as patients face a lifetime of dietary restrictions, medication dependence, and reduced quality of life that extends far beyond the period of drug use.
When pharmaceutical companies fail to adequately warn about serious risks like gastroparesis, you deserve skilled legal representation that understands both the complex medicine and intricate law surrounding dangerous drug cases. OnderLaw has recovered over $5 billion in negotiated settlements for clients harmed nationwide, combining compassionate client service with aggressive litigation strategies that hold corporate defendants accountable.
Our attorneys work on contingency, meaning you pay no upfront costs and no attorney fees unless we successfully recover compensation for your injuries. We understand the physical, emotional, and financial toll that gastroparesis takes on your life, and we’re committed to fighting for maximum compensation while you focus on healing.
Missouri’s five-year statute of limitations for product liability claims (RSMo §516.120) might seem generous, but evidence quality deteriorates over time—medical records get archived or destroyed, witnesses’ memories fade, and digital communications disappear—making early case development essential for building strong claims.
Call (314) 408-6136 today for a free, confidential consultation where we’ll evaluate your case, explain your legal options, and answer all your questions without any obligation to proceed—because you deserve advocates who put your recovery first.
Our free consultation helps you understand your rights and options.
